Dernières nouvelles pour CNFinance Hldgs (NYSE:CNF) Stock

CNFinance Hldgs

CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.

CNFinance Holdings Limited American Depositary Shares, each representing twenty (20) Ordinary Shares

CNFinance Holdings Ltd

CANAFARMA HEMP PRODS by CANAFARMA HEMP PRODS CORP.

CanaFarma Hemp Products Corp

CHINA NONFERROUS MNING CP by China Nonferrous Mining Corp Ltd.

China Nonferrous Mining Corp Ltd

CFN ENTERPRISES INC by CFN ENTERPRISES INC.

CFN Enterprises Inc

Conifer Holdings Inc

Conifer Holdings, Inc. - 9.75% Senior Unsecured Notes due 2028

<p>Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) has outperformed the market over the past 5 years by 3.16% on an annualized basis producing an average annual return of 17.06%. Currently, Primerica has a market capitalization of $9.05 billion. </p>
<p><strong>Buying $100 In PRI:</strong> If an investor had bought $100 of PRI stock 5 years ago, it would be worth <strong>$222.35</strong> today based on a price of $267.46 for PRI at the time of writing.</p>
<h3>Primerica's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728333018_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

Trading Ideas

Here's How Much You Would Have Made Owning Primerica Stock In The Last 5 Years

<p>Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) has outperformed the market over the past 20 years by 2.71% on an annualized basis producing an average annual return of 11.23%. Currently, Williams-Sonoma has a market capitalization of $18.90 billion. </p>
<p><strong>Buying $100 In WSM:</strong> If an investor had bought $100 of WSM stock 20 years ago, it would be worth <strong>$826.17</strong> today based on a price of $149.62 for WSM at the time of writing.</p>
<h3>Williams-Sonoma's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728333012_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In Williams-Sonoma 20 Years Ago Would Be Worth This Much Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RSSFF"><strong>Affinor Growers</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 26.41% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/LMLLF"><strong>Pharmadrug</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 20.44% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CWBHF"><strong>Charlottes Web Holdings</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 17.65% at $0.13</li>
<li><a href="https://www.benzinga.com/quote/ZLDAF"><strong>Zelira Therapeutics</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDAF#OTC">ZLDAF</a>) shares closed up 15.28% at $0.55</li>
<li><a href="https://www.benzinga.com/quote/TGIFF"><strong>1933 Industries</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 12.25% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GENE"><strong>Genetic Technologies</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares closed up 7.59% at $0.73</li>
<li><a href="https://www.benzinga.com/quote/KAYS"><strong>Kaya Holdings</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 7.33% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/RMHB"><strong>Rocky Mountain High</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 5.56% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CBDY"><strong>Target Group</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 4.17% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ITHUF"><strong>iAnthus Capital Hldgs</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 3.38% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/EAST"><strong>Eastside Distilling</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed up 3.28% at $0.57</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/SOLCF"><strong>SOL Glb Inv</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 10.18% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/FFNTF"><strong>4Front Ventures</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 8.76% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/ZDPY"><strong>Zoned Props</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 7.30% at $0.50</li>
<li><a href="https://www.benzinga.com/quote/CURR"><strong>Currenc Group</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 6.93% at $2.27</li>
<li><a href="https://www.benzinga.com/quote/UGRO"><strong>Urban-gro</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 6.76% at $1.42</li>
<li><a href="https://www.benzinga.com/quote/ELLXF"><strong>Elixinol Wellness</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 6.15% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CARA"><strong>Cara Therapeutics</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed down 5.66% at $0.27</li>
<li><a href="https://www.benzinga.com/quote/SOL"><strong>Emeren Group</strong></a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed down 4.53% at $2.73</li>
<li><a href="https://www.benzinga.com/quote/MRMD"><strong>MariMed</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 4.46% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CXXIF"><strong>C21 Investments</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 3.91% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/CGC"><strong>Canopy Gwth</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 3.85% at $4.20</li>
<li><a href="https://www.benzinga.com/quote/YCBD"><strong>cbdMD</strong></a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 3.29% at $0.46</li>
<li><a href="https://www.benzinga.com/quote/RIV"><strong>Rivernorth Opps Fund</strong></a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#NYSE">RIV</a>) shares closed down 3.28% at $12.86</li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cannabis

Markets

Movers

CARA

CBDY

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CWBHF

CXXIF

EAST

ELLXF

FFNTF

GENE

ITHUF

KAYS

LMLLF

MRMD

RMHB

RSSFF

SOLCF

TGIFF

UGRO

YCBD

ZDPY

ZLDAF

Marijuana Stock Movers For October 7, 2024

<p>Wells Fargo  analyst Sam Reid   maintains Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) with a Equal-Weight and raises the price target from $165 to $175.</p>


Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Owens-Corning, Raises Price Target to $175

<p>This Comparable RevPAR reflects an approximate decrease of&nbsp;1.6%&nbsp;compared to the&nbsp;third quarter&nbsp;of 2023.&nbsp;</p>
<p>Additionally, for the month of&nbsp;July 2024, Comparable RevPAR increased approximately&nbsp;0.3%&nbsp;versus&nbsp;July 2023. For the month of&nbsp;August 2024, Comparable RevPAR decreased approximately&nbsp;2.1%&nbsp;versus&nbsp;August 2023. For the month of&nbsp;September 2024, Comparable RevPAR decreased approximately&nbsp;3.0%&nbsp;versus&nbsp;September 2023. &nbsp;</p>
<p>Further, as previously announced, the Company commenced the offering of its Non-Traded Preferred Equity during the&nbsp;third quarter&nbsp;of 2022.&nbsp;</p>


Ashford Hospitality Trust Expects To Report Occupancy Of Approximately 71% For Q3 With Average Daily Rate Of $187 Resulting In RevPAR Of Approximately $132

<p>Wells Fargo  analyst Sam Reid   maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Overweight and raises the price target from $90 to $92.</p>


Wells Fargo Maintains Overweight on Masco, Raises Price Target to $92

WIIM

PENN

PENN Entertainment shares are trading higher after the company reportedly guided Q3 retail operations adjusted EBITDAR of $465M-$475M.

<p>Wells Fargo  analyst Joe O'Dea   maintains Trane Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) with a Underweight and raises the price target from $320 to $360.</p>


Wells Fargo Maintains Underweight on Trane Technologies, Raises Price Target to $360

<p>Wells Fargo  analyst Joseph O'Dea   maintains Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) with a Equal-Weight and lowers the price target from $110 to $104.</p>


Wells Fargo Maintains Equal-Weight on Stanley Black & Decker, Lowers Price Target to $104

<p>Researchers from Emory University, the University of Wisconsin-Madison and UC-Berkeley have identified a significant opportunity for <a href="https://www.benzinga.com/topic/psilocybin-assisted-therapy">psilocybin-assisted therapy</a> in the U.S. mental healthcare landscape. As U.S. News <a href="https://www.usnews.com/news/health-news/articles/2024-09-13/over-5-million-americans-could-benefit-if-psilocybin-approved-for-depression-study">reported</a>, if approved by the <a href="https://www.benzinga.com/topic/food-and-drug-administration">FDA</a>, psilocybin could be used to treat depression, with an estimated<strong> 5.1 to 5.6 million</strong> Americans potentially benefiting from the therapy.</p>
<p>Examining a group of patients undergoing treatment for depression, researchers determined that psilocybin could be a game-changing solution, particularly for individuals suffering from major depressive disorder (MDD) or treatment-resistant depression (TRD). These conditions, which affect millions across the country, are typically unresponsive to standard treatments, underscoring the urgent need for new solutions.</p>
<h3 class="wp-block-heading"><strong>A Breakthrough Approach To Treating Depression</strong></h3>
<p>The study, <a href="https://pp.genomicpress.com/wp-content/uploads/2024/09/PP0025-Rab-2024.pdf">published</a> in Psychedelics<em> </em>by Genomic Press, explored the FDA's consideration of psilocybin from <a href="https://www.benzinga.com/markets/cannabis/22/11/29549541/the-strongest-magic-mushroom-species">Psilocybe cubensis</a> mushrooms as a <a href="https://www.benzinga.com/general/biotech/24/03/37665900/fda-grants-cybin-breakthrough-therapy-status-for-major-depression-psilocybin-therapy-company-anno">breakthrough therapy,</a> which is a designation that allows drugs with the potential to address life-threatening conditions like severe depression, to be fast-tracked through the approval process. If green-lighted, psilocybin would likely be reserved for individuals with the most severe forms of depression or those who have not responded to traditional treatments.</p>
<p>The study found that some 1.7 million Americans with TRD could immediately benefit from psilocybin-assisted therapy. When including those with MDD, the number of potential beneficiaries rises to 5.6 million. <strong>Dr. Syed Fayzan Rab</strong>, an MD candidate at Emory University and the study's lead author, highlighted the importance of recognizing the scope of this opportunity. "This underscores the importance of understanding the practical realities of rolling out this novel treatment on a large scale."</p>
<h3 class="wp-block-heading"><strong>A Market Ready To Take Off</strong></h3>
<p>Implications of this study go beyond healthcare. The psilocybin-assisted therapy market holds immense economic potential. A 2023 <a href="https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1293243/full">report</a> estimated that a single psilocybin-assisted therapy session could cost around $1,500 per patient. Considering the millions of individuals who may be eligible for treatment, this could translate into billions of dollars in revenue once psilocybin gains FDA approval.</p>
<p>Several companies are already preparing to capitalize on this potential market. <strong>Compass Pathways</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>), <strong>Atai Life Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) and <strong>Mindset Pharma</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MSSTF#OTC">MSSTF</a>) are among the pharmaceutical firms actively developing psilocybin-based treatments. </p>
<h3 class="wp-block-heading"><strong>Beyond Depression: Psilocybin's Expanding Horizon</strong></h3>
<p>While psilocybin's most immediate application lies in depression treatment, its therapeutic potential extends further. Ongoing studies are investigating psilocybin's efficacy in treating chronic pain and <a href="https://www.benzinga.com/topic/ptsd">post-traumatic stress disorder</a>. These developments signal that psilocybin could revolutionize not just mental healthcare but also the treatment of other chronic conditions.</p>
<p>However, psilocybin remains classified as a <a href="https://www.benzinga.com/topic/controlled-substances-act">Schedule I</a> drug at the federal level, meaning it is considered to have no accepted medical use and a high potential for abuse. This classification, shared with substances like marijuana, heroin and <a href="https://www.benzinga.com/topic/lsd">LSD</a>, complicates the path toward legalizing its medical use. </p>
<p>Despite these federal restrictions, several U.S. states and local jurisdictions have <a href="https://www.benzinga.com/topic/psychedelics-decriminalization">decriminalized psilocybin</a> in recent years, signaling a growing push for policy reform at higher levels. </p>
<p>"It's our hope that these findings spur productive discussions and proactive preparations to optimize the benefit to patients while minimizing unintended consequences," said <strong>Dr. Charles Raison</strong>, a professor of psychiatry at the University of Wisconsin and co-author of the study.  </p>
<p><em>Cover image made with A</em>I</p>


Psychedelics

Regulations

Health Care

ATAI

CMPS

MSSTF

Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes

<p>Wells Fargo  analyst Joseph O'Dea   maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Overweight and raises the price target from $293 to $305.</p>


Wells Fargo Maintains Overweight on Rockwell Automation, Raises Price Target to $305

Guidance

Penn Entertainment Expects Q3 Retail Operations Adj EBITDAR In Range $465M-$475M

<ul>
<li><i>Companies jointly propose electric transmission projects to serve region's growing power demand through&nbsp;PJM's competitive planning process</i></li>
<li><i>Collaboration leverages expertise of industry leaders to propose comprehensive, cost-effective solutions that promote regional grid reliability</i></li>
</ul>
<p>RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Dominion Energy Virginia, American Electric Power and FirstEnergy Corp. have entered into an innovative joint planning agreement to propose several new regional electric transmission projects across multiple states within the PJM footprint.&nbsp;</p>
<p>The innovative collaboration comes at a time when efficient and cost-effective regional transmission development is essential and encouraged by the Federal Energy Regulatory Commission (FERC), the independent federal agency that regulates the interstate transmission of electricity.</p>
<p>Power demand in the PJM region is growing at an unprecedented pace due to rapid expansion of energy-intensive industries such as data centers, the electrification of transportation and heating, and increased manufacturing onshoring. At the same time, the region's power generation mix is changing as legacy generation is retired and more renewables are added to the grid.</p>


Dominion Energy, American Electric Power, FirstEnergy Reach Joint Planning Agreement To Propose Regional Transmission Projects Across PJM Footprint To Propose Comprehensive, Cost-Effective Solutions That Promote Regional Grid Reliability

ELAN

Elanco shares are trading higher after the company received FDA approval for Credelio Quattro broad-spectrum canine oral parasiticide in a monthly dose.

<div>
<div><strong>Nutanix</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntnx#NASDAQ">NTNX</a>) shares have returned 26.2% year to date, outperforming the broader Zacks Computer and Technology sector&#39;s appreciation of 23.4%.</div>
<div>NTNX shares have also outperformed the Zacks Computer &ndash; IT Services industry and its peers like <strong>Unisys</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uis#NYSE">UIS</a>), <strong>Evolv Technologies</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlv#NASDAQ">EVLV</a>) and <strong>Cerence</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crnc#NASDAQ">CRNC</a>).</div>
<div>Over the same time frame, Unisys has appreciated 0.2%, while Evolv Technologies and Cerence have declined 19.7% and 86.3%, respectively. The industry has appreciated 9.2% YTD.</div>
<div>NTNX&#39;s outperformance can be attributed to the steady adoption of hybrid cloud solutions, an increase in renewal and subscription business, and an expanding clientele.&nbsp;</div>
<div class="chart_embed">
<h2>Nutanix Price and Consensus</h2>
<p><img alt="Nutanix Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/a2/1728310394.png" style="height:265px; width:581px" title="" /></p>
<p>Nutanix price-consensus-chart | Nutanix Quote</p>
</div>
<h2>Does Strong Clientele Justify NTNX&#39;s Premium Valuation?</h2>
<div>In fiscal 2024, approximately 76% of NTNX&#39;s end customers who have been its clients for 18 months or longer made a repeat purchase, reflecting a loyal customer base. Nutanix&#39;s total revenues for fiscal 2024 were $2.14 billion, of which 93.8% was from subscriptions.</div>
<div>NTNX stacks are usable with a vast library of operating systems like Microsoft and SAP, and existing customers have benefited from the hyper-converged infrastructure market.</div>
<div>However, NTNX shares are overvalued, as suggested by a Value Score of F.</div>
<div>In terms of the forward 12-month Price/Earnings ratio, NTNX is trading at 178.5X, higher than the Zacks Computer &amp; Technology sector&#39;s 26.83X.</div>
<div>So, the question for investors is - does an expanding clientele make Nutanix shares attractive despite a stretched valuation? Let&#39;s analyze.</div>
<h2>NTNX&#39;s Cloud Innovation Aids Prospects</h2>
<div>Nutanix is focusing on new releases and enhancements to the Nutanix Cloud Platform to aid long-term opportunities and to become a leader in modern application and data management platforms.</div>
<div>NTNX expanded its 14-year partnership with Dell Technologies to announce innovations like Dell XC Plus and Dell PowerFlex.</div>
<div>Nutanix Cloud Platform enables businesses to modernize IP footprints, integrate hybrid cloud models, and accelerate migration of workload to the public cloud to enhance cost-effectiveness and efficiency.</div>
<div>NTNX recently launched GPT-in-a-Box to aid in streamlining the adoption of GenAI by enterprises. It also launched Nutanix Data Services for Kubernetes, to provide consistent data services across virtual machines and container assets, and Nutanix Kubernetes Platform to allow simplification in the management of modern applications on-premise and in native public cloud service.</div>
<div>Nutanix announced a collaboration with NVIDIA to aid enterprises adopt GenAI easily.</div>
<div>Nutanix Cloud Clusters enable workloads to run seamlessly in private and public clouds while increasing automation and reducing the dependency on expensive proprietary solutions.</div>
<h2>Elongated Sales Cycle Concern for Nutanix</h2>
<div>In fiscal 2024, Nutanix&#39;s land and expand revenues suffered due to longer sales cycles, which have been elongated compared to historical levels.</div>
<div>NTNX&#39;s average contract term length in the fiscal fourth quarter was 3.1 years, 0.1 years higher than the fiscal third quarter.</div>
<div>Nutanix&#39;s customer base is increasing but is largely constituted of large deals leading to variability of timing and outcome.</div>
<div>As NTNX targets its sales efforts for large enterprises, it faces higher costs, greater competition, stiff price pressure, customization challenges, and lower predictability in its ability to complete the sale.</div>
<div>NTNX&#39;s operating expense for fiscal 2024 was $1.51 billion, up 7% over fiscal 2023. This increase can be attributed to an increase in research and development (increased 19% to $638 million) and sales and marketing expenses (increased 6% to $977 million). Higher operating expenses are likely to negatively impact bottom-line results in fiscal 2025.</div>
<h2>NTNX&#39;s Fiscal 2025 Outlook Positive</h2>
<div>For fiscal 2025, NTNX revenues are estimated in the range of $2.435-$2.465 billion, indicating year-over-year growth of 14% at the mid-point.</div>
<div>The Zacks Consensus Estimate for revenues is pegged at $2.45 billion, indicating year-over-year growth of 14.24%.</div>
<div>NTNX expects a non-GAAP operating margin in the band of 15.5-17%.</div>
<div>The consensus mark for fiscal 2025 earnings is pegged at $1.40 per share, up 2.9% in the past 30 days. The figure indicates a 6.87% year-over-year increase.</div>
<div>Nutanix expects free cash flow in the range of $540-$600 million, suggesting a free cash flow margin of 23% at the midpoint.</div>
<h2>NTNX Shares - To Buy, Hold or Sell?</h2>
<div>Macroeconomic challenges, including persistent inflation, are a concern for NTNX&#39;s prospects.</div>
<div>Stretched valuation, elongated sales cycle duration, and increasing operating expenses are concerns for investors.</div>
<div>Nutanix currently has a Zacks Rank #3 (Hold), which implies that investors should wait for a more favorable entry point into the stock.</div>
<div><a href="https://www.zacks.com/stock/news/2347040/nutanix-shares-up-26-ytd-how-should-investors-play-the-stock?cid=CS-BENZ-FT-analyst_blog|rank_focused-2347040">To read this article on Zacks.com click here.</a></div>
</div>


Earnings

Large Cap

Macro Economic Events

Penny Stocks

Contracts

Small Cap

Economics

Tech

CRNC

EVLV

NTNX

Nutanix Shares Up 26% YTD: How Should Investors Play the Stock?

<p>Wells Fargo  analyst Joseph O'Dea   maintains Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with a Overweight and raises the price target from $640 to $710.</p>


Wells Fargo Maintains Overweight on Parker Hannifin, Raises Price Target to $710

<ul>
<li>Credelio Quattro&#x2122; (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms, roundworms, hookwormsii and three different species of tapeworm that other brands skip creating a gap in coverageiii</li>
<li>Warming temperatures and changing consumer habits have increased parasite pressure and spread across geographies, bringing with them increased public health risk.</li>
<li>Experts recommend monthly treatment for zoonotic parasitesiv, like <i>Echinococcus granulosus</i>, a type of tapeworm.</li>
<li>Credelio Quattro launch expected in first quarter of 2025</li>
</ul>
<p>GREENFIELD, Ind., Oct. 7, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) today announced the U.S. Food and Drug Administration (FDA) has approved Credelio Quattro&#x2122; (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), becoming the broadest approved canine oral parasiticide with its protection against six types of parasites—fleas, ticks, heartworms, and the three risky intestinal parasites—roundworms, hookwormsii and tapeworms. Credelio Quattro is a single, monthly chewable tablet for dogs eight weeks of age or older.</p>


Biotech

General

Elanco Receives FDA Approval For Credelio Quattro, The Broadest Canine Oral Parasiticide Protection In A Single Monthly Dose; Launch Expected In Q1 2025

<p>Wells Fargo  analyst Joseph O'Dea   maintains Otis Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) with a Equal-Weight and raises the price target from $95 to $108.</p>


OTIS

Wells Fargo Maintains Equal-Weight on Otis Worldwide, Raises Price Target to $108

<p>Wells Fargo  analyst Joseph O'Dea   maintains Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) with a Equal-Weight and raises the price target from $570 to $615.</p>


Wells Fargo Maintains Equal-Weight on Lennox Intl, Raises Price Target to $615

<p><strong>Sonder Holdings Inc. (NASDAQ:</strong><a href="https://www.benzinga.com/stock/SOND#NASDAQ"><strong>SOND</strong></a><strong>, "Sonder" or the "Company"))) </strong>today announced that it has received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that since it remains delinquent in filing its Forms 10-Q for the periods ended March 31 and June 30, 2024 (the "Forms 10-Q"), respectively (the "Delinquent Filings"), the Staff has determined that the Company is non-compliant with Nasdaq Listing Rule 5250(c)(1). Previously, the Staff granted the Company an exception until September 30, 2024, to file all delinquent periodic reports. Additionally, the Company was previously deemed delayed on the filing of the&nbsp;Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"); however, the Company has since filed the 2023 Form 10-K on September 27, 2024, and the Staff determined that the Company complies with respect to the 2023 Form 10-K. As a result of the Delinquent Filings, the Company's common stock and warrants are subject to suspension in trading on October 10, 2024, and delisting from Nasdaq unless the Company appeals and requests a hearing before a Hearings Panel ("Hearings Panel") by 4:00 Eastern Time on October 8, 2024.</p>


SOND

Sonder Holdings Receives Nasdaq Staff Determination Letter; Has Requested Hearing Before Hearings Panel

Cnfinance Holdings (CNF) has released an update. CNFinance Holdings Limited, a front-runner in China's home equity loan market, has filed its annua...

CNFinance Reports Annual Fiscal Milestone

Warning: CNF is at high risk of performing badly

Trupanion, CNFinance among financial movers

Root, Applied Digital among financial movers

CNFinance GAAP EPADS of $0.10

CNFinance Holdings (CNF) has released an update. CNFinance Holdings Limited reported an increase in outstanding loan principal by 9.6%, reaching RM...

CNFinance Reports Growth Amid Economic Challenges

CNFinance Holdings Limited (CNF) Q2 2024 Earnings Call Transcript

AGBA

APLD

BTOG

FUFU

HMNF

OXBR

PLTN

ROOT

RWOD

SEPA

SNTG

SWIN

TRUP

UMAC

Press Releases

CNFinance to Report Third Quarter of 2023 Financial Results on Wednesday, November 29, 2023

CNFinance Announces Third Quarter of 2023 Unaudited Financial Results

Fintech

Real Estate

CNFinance to Report Fourth Quarter and Fiscal Year of 2023 Financial Results on Thursday, March 28, 2024

CNFinance Announces Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results

CNFinance Files Annual Report on Form 20-F for Fiscal Year 2023

CNFinance to Hold Annual General Meeting on June 7, 2024

CNFinance Announces Expansion of Share Repurchase Program

CNFinance to Report the First Half of 2024 Financial Results on Tuesday, August 27, 2024

CNFinance Announces First Half of 2024 Unaudited Financial Results

Enact Holdings

Federal Agricultural Mortgage Corporation Common Stock

Federal Agricultural

Better Home & Finance Holding Company - Class A Common Stock

Better Home & Finance

Mr. Cooper Gr

Essent Group

Finance of America Companies Inc. Class A Common Stock

Finance of America

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Comments

CNFinance Hldgs

Actualités

Dernières nouvelles pour CNFinance Hldgs (NYSE:CNF) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL